In the present study, we investigated the feasibility of generating third-generation CAR-NK-92 cells targeting CD19 and CD138 as well as dual CAR-NK-92 cells cotargeting CD19 and CD138 and evaluated their selective cytotoxicity in vitro toward various hematologic cancer cells with different CD19 and CD138 expression profiles. This evidence concerns the gene SDC1 and hematopoietic and lymphoid cell neoplasm.